The Latest Breaking News from ABBV

As the global population ages and faces the increasing toll of chronic diseases, the pharmaceutical industry is expected to step up to meet people’s healthcare needs. Against this backdrop, pharma companies like Novo Nordisk (NVO), AbbVie (ABBV), and Novartis (NVS) could boost your portfolio. Read on….

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

It’s the last day of the trading week, so investors are looking for extra spending money for the weekend ahead. Here are three unusually active put options to sell: high-paying and worthwhile long-term holds.

Due to the emergence of new technologies and the introduction of generic medicines, the pharma industry seems well-positioned to witness growth. While pharma stocks should benefit from the industry tailwinds, let us analyze whether AbbVie (ABBV) is a better buy than Pfizer (PFE).

The pharma industry performs relatively well during downturns due to inelastic demand for its products and services. Therefore, fundamentally strong pharma stocks Novo Nordisk (NVO), AbbVie (ABBV), and Novartis (NVS) might be profitable buys. Read on.

With the growing prevalence of chronic conditions, an aging population, widespread adoption of digital technologies, and several R&D efforts, the pharmaceutical industry is poised for exponential growth and expansion. So, let’s compare leading pharma stocks AbbVie (ABBV) and Pfizer (PFE) to identify which is a better investment now. Keep reading….

These 3 dividend stocks have uninterruptedly paid and raised their dividends for years. Further, these stocks have outperformed the broader markets, and Wall Street analysts have a favorable outlook on them.

The pharmaceutical industry’s inelastic demand for its products helps it to weather economic downturns. With fears of an impending recession playing on the minds of investors, it could be wise to buy fundamentally strong pharmaceutical stock AbbVie (ABBV). On the other hand, given its mixed fundamentals and profitability, it could…

The best retirement stocks ideally have attractive dividends that can be sustained. This can lead to steady income and long-term value for retirees.

Barchart.com’s Unusual Options Activity on Wednesday had 18 AbbVie call options in the Top 100. Not everyone believes it’s an excellent time to buy ABBV stock. Yesterday’s options market says otherwise.

Amidst the turmoil in the banking sector, high inflation, and the Fed’s restrictive monetary policy, the economy faces a threat of recession this year. However, fundamentally strong stocks AbbVie (ABBV) and Salesforce (CRM) might be worth adding to your watchlist. Read more.